输血对经导管或外科主动脉瓣置换术后死亡率的影响
基于SURTAVI试验1660例中危重度主动脉瓣狭窄患者的随机对照数据,比较输血与未输血者的30天及后期全因和心血管死亡率。校正混杂因素后,输血与30天死亡率相关但非独立于手术并发症,提示输血是风险标志而非独立危险因素。
要点
- 输血患者年龄更大、女性更多、衰弱及合并症更多,STS预测死亡率评分更高。
- 校正差异后,输血与30天死亡率相关,但30天后无关联。
- 输血对30天死亡率的影响非独立于手术并发症(HR 21.04)。
核心结论
- 输血未独立增加主动脉瓣置换术后死亡风险,更可能是慢性疾病和围术期并发症的风险标志。
研究设计与样本
- SURTAVI随机对照试验的事后分析,纳入1660例中危症状性重度主动脉瓣狭窄患者,随机接受经导管或外科主动脉瓣置换。
主要发现
- 输血组年龄更大、女性更多、衰弱及合并症更多,STS预测死亡率评分更高。
- 校正差异后,输血与30天死亡率相关,但30天后无关联。
临床怎么用
- 临床应关注输血所提示的慢性病状态和围术期并发症,而非将输血本身视为独立死亡危险因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: An increasing body of evidence suggests that packed red blood cell (PRBC) transfusion may be associated with increased morbidity and mortality after transcatheter and surgical aortic valve replacement. It remains unclear whether PRBC transfusion is a surrogate marker or truly an independent risk factor for mortality after aortic valve replacement in different populations. METHODS: The Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) trial randomized 1660 patients with symptomatic, severe aortic stenosis at intermediate risk for operative death to transcatheter aortic valve replacement or surgical aortic valve replacement. Baseline characteristics and outcomes including all-cause and cardiovascular mortality at 30 days and thereafter were compared between participants with and participants without PRBC transfusion. Cox proportional hazards models with time-varying covariates were fitted to estimate the effect of PRBC transfusion on mortality after adjustment for comorbidities and procedural complications. RESULTS: Patients receiving PRBC were older, more commonly female and frail, with more comorbidities. The Society of Thoracic Surgeons Predicted Risk of Mortality baseline score was higher in the transfused group. After adjustment for these differences, PRBC transfusion was associated with mortality at 30 days, but not thereafter. The effect of PRBC on mortality (hazard ratio 1.04; 95% confidence interval, 0.96 to 1.11; P = .304) at 30 days was not independent of procedural complications (hazard ratio 21.04; 95% CI, 7.26 to 60.95; P < .001). CONCLUSIONS: Poor health status, procedural complications, PRBC transfusion, and mortality are correlated with each other. Transfusion of PRBC did not independently increase risk for mortality. In this intermediate-risk population, transfusion appears to be a risk marker of chronic conditions and periprocedural complications as opposed to a risk factor for postprocedural mortality. (Clinical trial registration: www.clinicaltrials.gov NCT01586910.).
引用
- Mumtaz M, Wyler von Ballmoos MC, Deeb GM, et al. The Impact of Transfusions on Mortality After Transcatheter or Surgical Aortic Valve Replacement. Ann Thorac Surg. 2020. PMID: 33217396. doi:10.1016/j.athoracsur.2020.09.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。